Skip to main content
Year archive

BerGenBio — 2020 filings

All 213 regulatory filings released by BerGenBio (BGBIO) in 2020, sourced directly from the official regulator.

213 Filings
2020 Period
2020 filings (213)
Filing Released Lang
Financial calendar
Report Publication Announcement
2020-12-21 English
Flaggemelding - BGBIO
Director's Dealing
2020-12-16 Norwegian
BERGENBIO TO PRESENT AN UPDATE ON THE ONGOING PHASE II STUDY OF BEMCENTINIB IN COMBINATION WITH PEMBROLIZUMAB IN REFRACTORY NSCLC AT WCLC 2020
Regulatory Filings
2020-12-16 English
BERGENBIO TO PRESENT AN UPDATE ON THE ONGOING PHASE II STUDY OF BEMCENTINIB IN COMBINATION WITH PEMBROLIZUMAB IN REFRACTORY NSCLC AT WCLC 2020
Regulatory Filings
2020-12-16 English
BERGENBIO ASA: EXTRAORDINARY GENERAL MEETING
AGM Information
2020-12-09 English
BERGENBIO ASA: EXTRAORDINARY GENERAL MEETING
AGM Information
2020-12-09 Norwegian
BERGENBIO ASA: EXTRAORDINARY GENERAL MEETING
AGM Information
2020-12-09 English
BerGenBio ASA: Extraordinary General Meeting today
AGM Information
2020-12-09 English
BerGenBio ASA: Extraordinary General Meeting today
AGM Information
2020-12-09 English
BerGenBio bekrefter første pasient rekruttert med bemcentinib i ACCORD klinisk studie
Regulatory Filings
2020-12-08 Norwegian
BERGENBIO CONFIRMS FIRST COVID-19 PATIENT ENROLLED WITH BEMCENTINIB IN ACCORD TRIAL
Regulatory Filings
2020-12-08 English
BerGenBio bekrefter første pasient rekruttert med bemcentinib i ACCORD klinisk studie
Regulatory Filings
2020-12-08 Norwegian
BERGENBIO CONFIRMS FIRST COVID-19 PATIENT ENROLLED WITH BEMCENTINIB IN ACCORD TRIAL
Regulatory Filings
2020-12-08 English
BERGENBIO PRESENTS UPDATED CLINICAL DATA FROM TWO PHASE II STUDIES OF BEMCENTINIB IN AML AND MDS PATIENTS AT ASH 2020
Regulatory Filings
2020-12-06 English
BerGenBio presenterer oppdaterte kliniske data fra to fase-II kombinasjonsstudier av bemcentinib i AML og MDS pasienter på ASH 2020 konferansen
Regulatory Filings
2020-12-06 Norwegian
BERGENBIO PRESENTS UPDATED CLINICAL DATA FROM TWO PHASE II STUDIES OF BEMCENTINIB IN AML AND MDS PATIENTS AT ASH 2020
Regulatory Filings
2020-12-06 English
BerGenBio presenterer oppdaterte kliniske data fra to fase-II kombinasjonsstudier av bemcentinib i AML og MDS pasienter på ASH 2020 konferansen
Regulatory Filings
2020-12-06 Norwegian
BERGENBIO TO PRESENT AT UPCOMING HEALTHCARE CONFERENCES IN DECEMBER 2020
Regulatory Filings
2020-12-03 English
BERGENBIO TO PRESENT AT UPCOMING HEALTHCARE CONFERENCES IN DECEMBER 2020
Regulatory Filings
2020-12-03 English
BERGENBIO TO PRESENT UPDATED CLINICAL DATA AT ASH 2020 MEETING
Regulatory Filings
2020-11-30 English
BERGENBIO TO PRESENT UPDATED CLINICAL DATA AT ASH 2020 MEETING
Report Publication Announcement
2020-11-30 English
BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTINIB AS A POTENTIAL TREATMENT FOR COVID-19 IN INDIA
Regulatory Filings
2020-11-24 English
BerGenBio bekrefter første pasient rekruttert i fase-II studie av bemcentinib som en potensiell behandling av COVID-19 pasienter i India
Regulatory Filings
2020-11-24 Norwegian
BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTINIB AS A POTENTIAL TREATMENT FOR COVID-19 IN INDIA
Regulatory Filings
2020-11-24 English
BerGenBio bekrefter første pasient rekruttert i fase-II studie av bemcentinib som en potensiell behandling av COVID-19 pasienter i India
Regulatory Filings
2020-11-24 Norwegian
BerGenBio ASA: Notice of Extraordinary General Meeting
AGM Information
2020-11-18 English
BerGenBio ASA: Notice of Extraordinary General Meeting
Proxy Solicitation & Information Statement
2020-11-18 English
BerGenBio ASA: Notice of Extraordinary General Meeting
AGM Information
2020-11-18 English
BERGENBIO ASA: THIRD QUARTER 2020 RESULTS
Earnings Release Q3 2020
2020-11-17 English
BERGENBIO ASA: THIRD QUARTER 2020 RESULTS
Interim / Quarterly Report Q3 2020
2020-11-17 English
BERGENBIO ASA: THIRD QUARTER 2020 RESULTS
Earnings Release Q3 2020
2020-11-17 English
BERGENBIO PRESENTS PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT ANNUAL SITC MEETING
Regulatory Filings
2020-11-11 English
BerGenBio presenterer fase-II bemcentinib kombinasjonsstudie i ikke-småcellet lungekreft (NSCLC) på den årlige SITC konferansen
Investor Presentation
2020-11-11 Norwegian
BERGENBIO PRESENTS PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT ANNUAL SITC MEETING
Regulatory Filings
2020-11-11 English
BerGenBio presenterer fase-II bemcentinib kombinasjonsstudie i ikke-småcellet lungekreft (NSCLC) på den årlige SITC konferansen
Regulatory Filings
2020-11-11 Norwegian
BERGENBIO HOSTING VIRTUAL R&D DAY TODAY
Report Publication Announcement
2020-11-06 English
BERGENBIO HOSTING VIRTUAL R&D DAY TODAY
Report Publication Announcement
2020-11-06 English
BerGenBio presenterer oppdaterte kliniske data fra fase-II kombinasjonsstudien av bemcentinib og LDAC hos eldre pasienter med tilbakevennende AML på ASH 2020 konferansen
Report Publication Announcement
2020-11-04 Norwegian
BERGENBIO TO PRESENT UPDATED CLINICAL DATA FROM ITS PHASE II COMBINATION TRIAL OF BEMCENTINIB AND LDAC IN ELDERLY RELAPSED AML PATIENTS AT ASH 2020 MEETING
Report Publication Announcement
2020-11-04 English
BerGenBio presenterer oppdaterte kliniske data fra fase-II kombinasjonsstudien av bemcentinib og LDAC hos eldre pasienter med tilbakevennende AML på ASH 2020 konferansen
Regulatory Filings
2020-11-04 Norwegian
BERGENBIO TO PRESENT UPDATED CLINICAL DATA FROM ITS PHASE II COMBINATION TRIAL OF BEMCENTINIB AND LDAC IN ELDERLY RELAPSED AML PATIENTS AT ASH 2020 MEETING
Regulatory Filings
2020-11-04 English
BERGENBIO ASA: INVITATION TO THIRD QUARTER 2020 RESULTS
Report Publication Announcement
2020-11-03 English
BERGENBIO ASA: INVITATION TO THIRD QUARTER 2020 RESULTS
Report Publication Announcement
2020-11-03 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-10-30 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-10-28 English
Flagging
Director's Dealing
2020-10-27 Norwegian
BERGENBIO VIRTUAL R&D DAY - 06 NOVEMBER 2020
Report Publication Announcement
2020-10-23 English
BERGENBIO VIRTUAL R&D DAY - 06 NOVEMBER 2020
Report Publication Announcement
2020-10-23 English
BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTINIB AS A POTENTIAL TREATMENT FOR COVID-19 PATIENTS IN SOUTH AFRICA
Regulatory Filings
2020-10-21 English
BerGenBio bekrefter første pasient registrert i fase-II studie av bemcentinib som en potensiell behandling for COVID-19 pasienter i Sør-Afrika
Regulatory Filings
2020-10-21 Norwegian
BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTINIB AS A POTENTIAL TREATMENT FOR COVID-19 PATIENTS IN SOUTH AFRICA
Regulatory Filings
2020-10-21 English
BerGenBio bekrefter første pasient registrert i fase-II studie av bemcentinib som en potensiell behandling for COVID-19 pasienter i Sør-Afrika
Regulatory Filings
2020-10-21 Norwegian
BERGENBIO TO PRESENT CLINICAL TRANSLATIONAL DATA FROM THE ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT ANNUAL SITC MEETING
Regulatory Filings
2020-10-15 English
BerGenBio presenterer kliniske translasjonsdata fra den pågående fase-II kombinasjonsstudien i ikke-småcellet lungekreft (NSCLC) under den årlige SITC konferansen
Investor Presentation
2020-10-15 Norwegian
BERGENBIO TO PRESENT CLINICAL TRANSLATIONAL DATA FROM THE ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT ANNUAL SITC MEETING
Regulatory Filings
2020-10-15 English
BerGenBio presenterer kliniske translasjonsdata fra den pågående fase-II kombinasjonsstudien i ikke-småcellet lungekreft (NSCLC) under den årlige SITC konferansen
Regulatory Filings
2020-10-15 Norwegian
BERGENBIO PRESENTS DATA ON ANTI-AXL ANTIBODY TILVESTAMAB AT 32[nd] ENA SYMPOSIUM
Regulatory Filings
2020-10-14 English
BerGenBio presenterer data om anti-AXL antistoff tilvestamab på 32[nd] ENA symposium
Regulatory Filings
2020-10-14 Norwegian
BERGENBIO PRESENTS DATA ON ANTI-AXL ANTIBODY TILVESTAMAB AT 32[nd] ENA SYMPOSIUM
Regulatory Filings
2020-10-14 English
BerGenBio presenterer data om anti-AXL antistoff tilvestamab på 32[nd] ENA symposium
Regulatory Filings
2020-10-14 Norwegian
BerGenBio kunngjør første pasient dosert med bemcentinib i tilbakevendende malignt pleuralt mesoteliom (lungehinnekreft) i sponset fase-IIa utprøvingsstudie
Investor Presentation
2020-10-07 Norwegian
BerGenBio kunngjør første pasient dosert med bemcentinib i tilbakevendende malignt pleuralt mesoteliom (lungehinnekreft) i sponset fase-IIa utprøvingsstudie
Regulatory Filings
2020-10-07 Norwegian
BERGENBIO ANNOUNCES FIRST PATIENT DOSED WITH BEMCENTINIB IN RELAPSED MALIGNANT PLEURAL MESOTHELIOMA INVESTIGATOR SPONSORED PHASE IIA STUDY
Regulatory Filings
2020-10-07 English
BERGENBIO ANNOUNCES FIRST PATIENT DOSED WITH BEMCENTINIB IN RELAPSED MALIGNANT PLEURAL MESOTHELIOMA INVESTIGATOR SPONSORED PHASE IIA STUDY
Regulatory Filings
2020-10-07 English
BerGenBio får regulatorisk godkjenning til å starte fase II forsøk av bemcentinib for COVID-19 i India
Regulatory Filings
2020-09-30 Norwegian
BerGenBio får regulatorisk godkjenning til å starte fase II forsøk av bemcentinib for COVID-19 i India
Regulatory Filings
2020-09-30 Norwegian
BerGenBio receIves regulatory approval to commence phase II trial of bemcentinib for COVID-19 in India
Regulatory Filings
2020-09-30 English
BerGenBio receIves regulatory approval to commence phase II trial of bemcentinib for COVID-19 in India
Regulatory Filings
2020-09-30 English
ACCORD KLINISK STUDIE AV BEMCENTINIB FOR COVID-19-PASIENTER GJENOPPTAS I STORBRITANNIA
Investor Presentation
2020-09-28 Norwegian
ACCORD KLINISK STUDIE AV BEMCENTINIB FOR COVID-19-PASIENTER GJENOPPTAS I STORBRITANNIA
Regulatory Filings
2020-09-28 Norwegian
ACCORD CLINICAL STUDY ASSESSING BEMCENTINIB IN COVID-19 PATIENTS TO RECOMMENCE IN UK
Regulatory Filings
2020-09-28 English
ACCORD CLINICAL STUDY ASSESSING BEMCENTINIB IN COVID-19 PATIENTS TO RECOMMENCE IN UK
Regulatory Filings
2020-09-28 English
BERGENBIO FÅR GODKJENNING FRA REK (REGIONAL ETISK KOMITÉ) FOR COVID-19 FORSØK I SØR-AFRIKA
Regulatory Filings
2020-09-24 Norwegian
BERGENBIO FÅR GODKJENNING FRA REK (REGIONAL ETISK KOMITÉ) FOR COVID-19 FORSØK I SØR-AFRIKA
Regulatory Filings
2020-09-24 Norwegian
BERGENBIO RECEIVES APPROVAL FROM NORWEGIAN REGIONAL ETHICS COMMITTEE FOR COVID-19 SOUTH AFRICA TRIAL
Regulatory Filings
2020-09-24 Norwegian
BERGENBIO RECEIVES APPROVAL FROM NORWEGIAN REGIONAL ETHICS COMMITTEE FOR COVID-19 SOUTH AFRICA TRIAL
Regulatory Filings
2020-09-24 English
BERGENBIO TO PRESENT AT SACHS ANNUAL BIOTECH IN EUROPE FORUM
Report Publication Announcement
2020-09-18 English
BERGENBIO TO PRESENT AT SACHS ANNUAL BIOTECH IN EUROPE FORUM
Regulatory Filings
2020-09-18 English
OSLO BØRS - MATCHING HALT ENDS
Regulatory Filings
2020-09-11 English
BERGENBIO FÅR GODKJENNING TIL Å STARTE FASE II FORSØK AV BEMCENTINIB FOR COVID-19 I SØR AFRIKA
Earnings Release Q3 2020
2020-09-11 Norwegian
BERGENBIO FÅR GODKJENNING TIL Å STARTE FASE II FORSØK AV BEMCENTINIB FOR COVID-19 I SØR AFRIKA
Regulatory Filings
2020-09-11 Norwegian
BERGENBIO RECEIVES APPROVAL TO COMMENCE PHASE II TRIAL OF BEMCENTINIB FOR COVID-19 IN SOUTH AFRICA
Legal Proceedings Report
2020-09-11 English
BERGENBIO RECEIVES APPROVAL TO COMMENCE PHASE II TRIAL OF BEMCENTINIB FOR COVID-19 IN SOUTH AFRICA
Regulatory Filings
2020-09-11 English
Matching Halt
Regulatory Filings
2020-09-11 English
BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES
Report Publication Announcement
2020-09-01 English
BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES
Regulatory Filings
2020-09-01 English
BerGenBio ASA: Primary Insider notification
Major Shareholding Notification
2020-08-19 English
BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2020
Interim / Quarterly Report H1 2020
2020-08-18 English
BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2020
Earnings Release H1 2020
2020-08-18 English
BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2020
Earnings Release H1 2020
2020-08-18 English
BerGenBios Bemcentinib oppfyller effektendepunktet i BERGAMO fase II-forsøk hos pasienter med høyrisiko myelodysplastiske syndromer eller akutt myeloide leukemi
Earnings Release Q3 2020
2020-08-18 Norwegian
BerGenBios Bemcentinib oppfyller effektendepunktet i BERGAMO fase II-forsøk hos pasienter med høyrisiko myelodysplastiske syndromer eller akutt myeloide leukemi
Earnings Release Q3 2020
2020-08-18 Norwegian
BerGenBio's Bemcentinib Meets Efficacy Endpoint in BERGAMO Phase II Trial with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia
Regulatory Filings
2020-08-18 English
BerGenBio's Bemcentinib Meets Efficacy Endpoint in BERGAMO Phase II Trial with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia
Regulatory Filings
2020-08-18 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-08-10 English
BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation
Report Publication Announcement
2020-08-10 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-08-05 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-08-04 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-08-03 English
BerGenBio ASA: Primary Insider notification
Major Shareholding Notification
2020-07-30 English
BerGenBio ASA: Primary Insider notification
Major Shareholding Notification
2020-07-29 English
BerGenBio ASA: Primary Insider notification
Major Shareholding Notification
2020-07-29 English
UPDATE ON BEMCENTINIB'S INVOLVEMENT IN POTENTIAL TREATMENT OF COVID-19 PANDEMIC
Legal Proceedings Report
2020-07-28 English
UPDATE ON BEMCENTINIB'S INVOLVEMENT IN POTENTIAL TREATMENT OF COVID-19 PANDEMIC
Regulatory Filings
2020-07-28 English
BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I/II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINIB
Regulatory Filings
2020-07-20 English
BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I/II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINIB
Regulatory Filings
2020-07-20 English
BerGenBio ASA: Registered share capital increase
Share Issue/Capital Change
2020-07-16 English
BerGenBio ASA: Registered share capital increase
Share Issue/Capital Change
2020-07-16 English
BerGenBio announces amendment to the ACCORD clinical trial protocol for BEMCENTINIB as potential treatment for COVID-19
Regulatory Filings
2020-07-08 English
BerGenBio announces amendment to the ACCORD clinical trial protocol for BEMCENTINIB as potential treatment for COVID-19
Regulatory Filings
2020-07-08 English
BerGenBio to present at Digital Novel Coronavirus Investment Forum
Report Publication Announcement
2020-07-07 English
BerGenBio to present at Digital Novel Coronavirus Investment Forum
Regulatory Filings
2020-07-07 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-07-06 English
BerGenBio ASA: Final results of the subsequent offering
Share Issue/Capital Change
2020-07-06 English
BerGenBio ASA: Final results of the subsequent offering
Share Issue/Capital Change
2020-07-06 English
BerGenBio ASA: Results of the subsequent offering
Share Issue/Capital Change
2020-07-03 English
BerGenBio ASA: Results of the subsequent offering
Share Issue/Capital Change
2020-07-03 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-07-03 English
BerGenBio ASA: Last day of subscription period in the subsequent offering
Share Issue/Capital Change
2020-07-03 English
BerGenBio ASA: Last day of subscription period in the subsequent offering
Share Issue/Capital Change
2020-07-03 English
BerGenBio ASA: Primary Insider notification
Major Shareholding Notification
2020-07-02 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-07-01 English
BERGENBIO ANNOUNCES POSITIVE interim CLINICAL AND TRANSlaTIONAL DATA from Phase II trial of BEMCENTINIB IN COMBINATION WITH KEYTRUDA[®] IN checkpoint inhibitor refractory NSCLC PATIENTS
Regulatory Filings
2020-06-25 English
BERGENBIO ANNOUNCES POSITIVE interim CLINICAL AND TRANSlaTIONAL DATA from Phase II trial of BEMCENTINIB IN COMBINATION WITH KEYTRUDA[®] IN checkpoint inhibitor refractory NSCLC PATIENTS
Earnings Release Q2 2020
2020-06-25 English
BerGenBio announces change to presentation time at Next Gen Immuno-Oncology Congress
Regulatory Filings
2020-06-24 English
BerGenBio announces change to presentation time at Next Gen Immuno-Oncology Congress
Regulatory Filings
2020-06-24 English
BerGenBio to Present at the Upcoming Virtual European Biotech Investor Day 2020
Regulatory Filings
2020-06-23 English
BerGenBio ASA: Commencement of the subsequent offering
Capital/Financing Update
2020-06-19 English
BerGenBio ASA: Commencement of the subsequent offering
Capital/Financing Update
2020-06-19 English
BerGenBio ASA: Approval of Prospectus
Share Issue/Capital Change
2020-06-19 English
BerGenBio ASA: Approval of Prospectus
Capital/Financing Update
2020-06-19 English
BerGenBio ASA: Resolution to carry out a share capital increase in connection with the Subsequent Offering
AGM Information
2020-06-19 Norwegian
BerGenBio ASA: Resolution to carry out a share capital increase in connection with the Subsequent Offering
Capital/Financing Update
2020-06-19 English
BerGenBio ASA: Resolution to carry out a share capital increase in connection with the Subsequent Offering
Capital/Financing Update
2020-06-19 English
BERGENBIO TO PRESENT TOP LINE TRANSLATIONAL PHASE II DATA WITH BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN NSCLC PATIENTS AT Next Gen Immuno-Oncology Congress
Regulatory Filings
2020-06-15 English
BERGENBIO TO PRESENT TOP LINE TRANSLATIONAL PHASE II DATA WITH BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN NSCLC PATIENTS AT Next Gen Immuno-Oncology Congress
Environmental & Social Information
2020-06-15 English
BerGenBio to present at ABG Sundal Collier Oncology seminar
Regulatory Filings
2020-06-09 English
BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL
Regulatory Filings
2020-06-02 English
BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL
Regulatory Filings
2020-06-02 English
BerGenBio ASA: Notice of Extraordinary general meeting
AGM Information
2020-05-29 Norwegian
BerGenBio ASA: Notice of Extraordinary general meeting
AGM Information
2020-05-29 Norwegian
BerGenBio ASA: Notice of Extraordinary general meeting
AGM Information
2020-05-29 English
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2020
Interim / Quarterly Report Q1 2020
2020-05-19 English
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2020
Earnings Release Q1 2020
2020-05-19 English
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2020
Earnings Release Q1 2020
2020-05-19 English
DISCLOSURE OF SHAREHOLDINGS
Major Shareholding Notification
2020-05-14 English
BERGENBIO ASA: Invitation to first quarter 2020 results webcast presentation
Report Publication Announcement
2020-05-13 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2020-05-11 Norwegian
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2020-05-11 English
BERGENBIO RAISES NOK500m (?45.4m) VIA AN OVER SUBSCRIBED PRIVATE PLACEMENT
Capital/Financing Update
2020-05-05 English
BERGENBIO ASA - KEY INFORMATION RELATED TO THE SUBSEQUENT OFFERING
Capital/Financing Update
2020-05-05 English
BERGENBIO ASA - KEY INFORMATION RELATED TO THE SUBSEQUENT OFFERING
Capital/Financing Update
2020-05-05 English
BERGENBIO ASA - PRIVATE PLACEMENT SUCCESSFULLY PLACED
Capital/Financing Update
2020-05-04 English
BERGENBIO ASA - PRIVATE PLACEMENT SUCCESSFULLY PLACED
Capital/Financing Update
2020-05-04 English
BerGenBio ASA - Updated corporated presentation
Report Publication Announcement
2020-05-04 English
BerGenBio ASA - Updated corporated presentation
Regulatory Filings
2020-05-04 English
BerGenBio ASA - Contemplated Private Placement
Share Issue/Capital Change
2020-05-04 English
BerGenBio ASA - Contemplated Private Placement
Capital/Financing Update
2020-05-04 English
BERGENBIO'S BEMCENTINIB SELECTED TO BE FAST-TRACKED AS POTENTIAL TREATMENT FOR COVID-19 THROUGH NEW NATIONAL UK GOVERNMENT CLINICAL TRIAL INITIATIVE
Investor Presentation
2020-04-29 English
BERGENBIO'S BEMCENTINIB SELECTED TO BE FAST-TRACKED AS POTENTIAL TREATMENT FOR COVID-19 THROUGH NEW NATIONAL UK GOVERNMENT CLINICAL TRIAL INITIATIVE
Regulatory Filings
2020-04-29 English
BERGENBIO'S BEMCENTINIB SELECTED TO BE FAST-TRACKED AS POTENTIAL TREATMENT FOR COVID-19 THROUGH NEW NATIONAL UK GOVERNMENT CLINICAL TRIAL INITIATIVE
Regulatory Filings
2020-04-28 English
BERGENBIO'S BEMCENTINIB SELECTED TO BE FAST-TRACKED AS POTENTIAL TREATMENT FOR COVID-19 THROUGH NEW NATIONAL UK GOVERNMENT CLINICAL TRIAL INITIATIVE
Regulatory Filings
2020-04-28 English
BerGenBio ASA: Share option grant
Share Issue/Capital Change
2020-04-14 English
BerGenBio ASA: Share option grant
Remuneration Information
2020-04-14 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2020-03-30 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2020-03-30 English
BERGENBIO TO PRESENT AT THE UPCOMING 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE
Regulatory Filings
2020-03-30 English
BERGENBIO PROVIDES COVID-19 IMPACT ASSESSMENT
Regulatory Filings
2020-03-27 English
BERGENBIO PROVIDES COVID-19 IMPACT ASSESSMENT
Regulatory Filings
2020-03-27 English
BerGenBio ASA: Annual general meeting
AGM Information
2020-03-16 Norwegian
BerGenBio ASA: Annual general meeting
AGM Information
2020-03-16 English
BerGenBio ASA: Final results of the subsequent offering
Share Issue/Capital Change
2020-03-13 English
BerGenBio ASA: Final results of the subsequent offering
Capital/Financing Update
2020-03-13 English
BerGenBio ASA: Results of the subsequent offering
Share Issue/Capital Change
2020-03-12 English
BerGenBio ASA: Results of the subsequent offering
Capital/Financing Update
2020-03-12 English
BerGenBio ASA: Last day of subscription period in the subsequent offering
Report Publication Announcement
2020-03-12 English
BerGenBio ASA: Last day of subscription period in the subsequent offering
Report Publication Announcement
2020-03-12 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-03-06 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-03-05 English
BerGenBio ASA: Primary Insider notification
Major Shareholding Notification
2020-03-04 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2020-03-03 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2020-03-02 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2020-03-02 English
BerGenBio ASA: Primary Insider notification
Major Shareholding Notification
2020-02-28 English
BerGenBio ASA: Commencement of the subsequent offering
Capital/Financing Update
2020-02-26 English
BerGenBio ASA: Commencement of the subsequent offering
Capital/Financing Update
2020-02-26 English
BerGenBio ASA: Approval of Prospectus
Capital/Financing Update
2020-02-26 English
BerGenBio ASA: Approval of Prospectus
Capital/Financing Update
2020-02-26 English
BerGenBio ASA (OSE: BGBIO): Notice of Annual General Meeting
AGM Information
2020-02-24 English
BerGenBio ASA (OSE: BGBIO): Notice of Annual General Meeting
AGM Information
2020-02-24 English
BerGenBio ASA (OSE: BGBIO): Notice of Annual General Meeting
AGM Information
2020-02-24 English
BerGenBio ASA (OSE:BGBIO): Annual Report 2019
Annual Report FY 2019
2020-02-24 English
BerGenBio ASA (OSE:BGBIO): Annual Report 2019
Report Publication Announcement FY 2019
2020-02-24 English
BerGenBio ASA: Board approval of 2019 annual financial statement
Report Publication Announcement
2020-02-21 English
BerGenBio ASA: Board approval of 2019 annual financial statement
Report Publication Announcement
2020-02-21 English
BERGENBIO ASA - Resolution to carry out a share capital increase in connection with the Private Placement and the Subsequent Offering
AGM Information
2020-02-20 English
BERGENBIO ASA - Resolution to carry out a share capital increase in connection with the Private Placement and the Subsequent Offering
Share Issue/Capital Change
2020-02-20 English
BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2019
Interim / Quarterly Report FY 2019
2020-02-11 English
BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2019
Earnings Release Q4 2019
2020-02-11 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2020-02-05 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2020-02-05 English
BERGENBIO ASA: Invitation to fourth quarter and full year 2019 results presentation and webcast
Report Publication Announcement
2020-02-03 English
BERGENBIO ASA: Invitation to fourth quarter and full year 2019 results presentation and webcast
Report Publication Announcement
2020-02-03 English
BerGenBio ASA (BGBIO): Notice of Extraordinary General Meeting
AGM Information
2020-01-30 Norwegian
BerGenBio ASA (BGBIO): Notice of Extraordinary General Meeting
AGM Information
2020-01-30 English
BERGENBIO ASA - KEY INFORMATION RELATED TO THE SUBSEQUENT OFFERING
Share Issue/Capital Change
2020-01-29 Norwegian
BERGENBIO ASA - KEY INFORMATION RELATED TO THE SUBSEQUENT OFFERING
Capital/Financing Update
2020-01-29 English
BERGENBIO ASA - PRIVATE PLACEMENT SUCCESSFULLY PLACED
Capital/Financing Update
2020-01-29 English
BERGENBIO ASA - PRIVATE PLACEMENT SUCCESSFULLY PLACED
Capital/Financing Update
2020-01-29 English
BERGENBIO ASA - CONTEMPLATED PRIVATE PLACEMENT
Capital/Financing Update
2020-01-29 English
BERGENBIO ASA - CONTEMPLATED PRIVATE PLACEMENT
Capital/Financing Update
2020-01-29 English
BERGENBIO MEETS EFFICACY ENDPOINT for FIRST STAGE OF PHASE II TRIAL WITH AXL INHIBITOR BEMCENTINIB IN COMBINATION WITH KEYTRUDA[®] IN NSCLC PATIENTS PROGRESSING ON IMMUNE CHECKPOINT INHIBITORS
Regulatory Filings
2020-01-15 English
BERGENBIO MEETS EFFICACY ENDPOINT for FIRST STAGE OF PHASE II TRIAL WITH AXL INHIBITOR BEMCENTINIB IN COMBINATION WITH KEYTRUDA[®] IN NSCLC PATIENTS PROGRESSING ON IMMUNE CHECKPOINT INHIBITORS
Investor Presentation
2020-01-15 English